Literature DB >> 7298300

Nondetection of infectious hepatitis B virus in a human hepatoma cell line producing hepatitis B surface antigen.

E Tabor, J A Copeland, G F Mann, C R Howard, J Skelly, P Snoy, A J Zuckerman, R J Gerety.   

Abstract

The PLC/PRF/5 human hepatoma cell line producing hepatitis B surface antigen (HBsAg) was studied to determine whether infectious hepatitis B virus (HBV) was also being produced. 2 chimpanzees with no previous exposure to HBV and no serologic markers of past or active HBV infection were inoculated intravenously with 50 ml of either tissue culture supernatant fluid (357 ng/ml HBsAg) or a suspension of cells disrupted by repeated freeze-thaw cycles (57 ng/ml HBsAg). No evidence of HBV infection was detected in either chimpanzee during 6 months of evaluation. This study suggests that the expression of a portion of the HBV genome, when a portion or all of that genome has been incorporated into a host cell, can result in the production of HBsAg without infectious HBV. If it becomes possible to produce a similar expression of this portion of the genome by itself in nonmalignant cells, HBsAg without HBV may be produced in vitro for use in hepatitis B vaccines.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298300     DOI: 10.1159/000149217

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  3 in total

Review 1.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

2.  Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.

Authors:  Avidan U Neumann; Sandra Phillips; Idit Levine; Samreen Ijaz; Harel Dahari; Rachel Eren; Shlomo Dagan; Nikolai V Naoumov
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Detection of HBsAg in a clone derived from the PLC/PRF/5 human hepatoma cell line.

Authors:  Y M Wen; J A Copeland; G F Mann; C R Howard; A J Zuckerman
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.